

Call for Entries

ASTELLAS RESEARCH COMPETITION SUPPORTS CANADIAN INVESTIGATORS



Markham, Ontario - April 8, 2010 - Astellas Pharma Canada recently announced the third annual **Astellas Research Competition (ARC)**, part of the company's sustained commitment to research and development within the Canadian scientific community. The Astellas Research Competition is consistent with the company's corporate mission of advancing scientific knowledge with the overarching objective of improving patient care and quality of life.

The Astellas Research Competition provides a platform of collaboration that supports innovative research ideas proposed by Canadian Investigators in two of Astellas' therapeutic franchises: Dermatology and Urology. Proposals will be reviewed based on scientific merit, clinical relevance, and feasibility. Successful applicants will receive funding up to a maximum amount of \$75,000 CDN for Urology studies and up to \$37,500 CDN for Dermatology studies.

Health care professionals who are interested in participating in this research competition are invited to review the application process and submit their proposals according to the guidelines provided by clicking the **Astellas Research Competition (ARC) link** <http://www.astellas.com/ca/arc/index.php> on the Astellas Pharma Canada website <http://www.astellas.com/ca/en>. The completed Application Form and Application Package can be submitted electronically to: astellas.research.competition@ca.astellas.com or by mail to: Astellas Pharma Canada Research Competition c/o Refaat Zaki, Clinical Sciences Associate, 675 Cochrane Drive Suite 500, West Tower, Markham, ON., L3R 0B8.

"It is an honour for Astellas Pharma Canada to support Canadian research and development and partner with talented investigators who are dedicated to solving medical challenges," said Fumiaki Sakurai, President of Astellas Pharma Canada. "The Astellas Research Competition, now in its third year, is creating opportunities for Canadian scientists to explore and validate new and more effective clinical therapies for those with skin disease and urological disorders. Together we are hoping to achieve better patient outcomes, and that is very rewarding".

The application deadline is 5 PM (EST) on **May 14, 2010** and the names of the award recipients will be posted on the Astellas Pharma Canada website at www.astellas.com on **June 18, 2010**. All applications must be submitted in English.

The award recipients for 2009 were:

IN UROLOGY

Dr. Lynn Stothers/Dr. Andrew Macnab, University of British Columbia, Bladder Care Centre; Vancouver, BC
Title: *Mathematical Modeling of Overactive Bladder using Near Infra-Red Spectroscopy (NIRS)*

Dr. Peter Pommerville, Victoria, British Columbia
Title: *Current Management Practices and Prescription Trends in the Treatment of Overactive Bladder (OAB) in British Columbia*

IN DERMATOLOGY

Dr. Wayne Gulliver, NewLab Clinical Research Inc.; St. John's, NFL

Title: *A cross sectional Study co morbidities associated with treatment groups of Psoriatic patients in a cohort of the Newfoundland and Labrador population*

Dr. Peter R. Hull, University of Saskatchewan, Department of Medicine, University of Saskatchewan; Saskatoon, SK

Title: *Filaggrin mutations and cell mediated, allergic, contact polysensitivity*

Dr. Sanjay Siddha, Toronto Western Hospital, UHN; Toronto, ON

Title: *Minimal erythema dose in Vitiligo affected & normal skin: comparison across phototypes*

About Astellas Pharma Canada, Inc.

Astellas Pharma Canada, Inc. is one of the Astellas Group of companies in North America and an affiliate of Astellas Pharma Inc., located in Tokyo. Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In Canada, Astellas has an intense focus on five key therapeutic areas - Immunology, Urology, Cardiology, Dermatology and Infectious Disease - and are considered leaders in these fields. For more information about Astellas Pharma Canada, Inc., please visit our website at www.astellas.com/ca.